The Krebs cycle is an amphibolic pathway operating in the mitochondrial matrix of all eukaryotic organisms. In response to proinflammatory stimuli, macrophages and dendritic cells undergo profound metabolic remodelling to support the biosynthetic and bioenergetic requirements of the cell. Recently, it has been discovered that this metabolic shift also involves the rewiring of the Krebs cycle to regulate cellular metabolic flux and the accumulation of Krebs cycle intermediates, notably, citrate, succinate and fumarate. Interestingly, a new role for Krebs cycle intermediates as signalling molecules and immunomodulators that dictate the inflammatory response has begun to emerge. This review will discuss the latest developments in Krebs cycle rewiring and immune cell effector functions, with a particular focus on the regulation of cytokine production.
Metabolic reprogramming in macrophages and DCs
Macrophages and dendritic cells (DCs) constitute two major components of the innate immune system responsible for sensing microbial compounds and the products of damaged tissue [1, 2] . The sensing of such products is achieved via the utilisation of multiple families of so-called pattern recognition receptors (PRRs), such as toll-like receptors (TLRs) [1, 2] . Several recent studies have implicated the global rewiring of metabolic pathways, elicited during the transition from a resting to an activated state, in response to the TLR ligand lipopolysaccharide (LPS) and other proinflammatory stimuli [2] . A well-characterised response to LPS is the shift away from the use of oxidative phosphorylation (OXPHOS) towards a glycolytic phenotype, termed aerobic glycolysis or the Warburg effect, thus tailoring cellular metabolism to suit the bioenergetic and biosynthetic demands of the cell ( Fig. 1 ) [2] [3] [4] . This metabolic switch also supports the diversion of glucose and glycolytic intermediates into the pentose phosphate pathway (PPP) [5, 6] . The PPP is an anabolic pathway that runs parallel to glycolysis and is essential to produce NADPH, an important cofactor in lipid biosynthesis, antioxidant defence, and nitric oxide (NO) and reactive oxygen species (ROS) production [5, 6] . The PPP also generates ribose 5-phosphate (R5P), an important precursor for nucleotide biosynthesis [5, 6] . The very first observation of increased glycolysis and decreased OXPHOS in macrophages occurred in 1969 [7] , and since then we have Abbreviations ACC, acetyl-CoA carboxylase; ACO, aconitase; BTA, 1,2,3-benzentricarboxylic acid; CIC, citrate carrier; COX2, cyclooxygenase 2; CS, citrate synthase; DCs, dendritic cells; ER, endoplasmic reticulum; ETC., electron transport chain; FH, fumarase; HAT, histone acetyltransferase; HDAC, histone deacetylase; IDH, isocitrate dehydrogenase; IFN-c, interferon-gamma; IMM, inner mitochondrial membrane; LPS, lipopolysaccharide; MDH, malate dehydrogenase; NO, nitric oxide; OGDH, a-ketoglutarate dehydrogenase; OXPHOS, oxidative phosphorylation; PDK1, pyruvate dehydrogenase kinase 1; PPP, pentose phosphate pathway; PQ, paraquat; PRRs, pattern recognition receptors; R5P, ribose 5-phosphate; ROS, reactive oxygen species; SDH, succinate dehydrogenase; SLP, substrate-level phosphorylation; SNPs, single nucleotide polymorphisms; TLRs, toll-like receptors.
garnered important molecular insights into the signalling pathways that govern this switch during both macrophage and DC activation. Here we describe these recent findings, with a renewed focus on the role of Krebs cycle intermediates in these critical immune and inflammatory cells.
Krebs cycle rewiring
Accompanying the downregulation of OXPHOS and metabolic remodelling is a dramatic change in cellintrinsic and -extrinsic metabolite levels, such as those that participate in the Krebs cycle (also known as the TCA or citric acid cycle), or those derived from Krebs cycle intermediates [8] [9] [10] . Elevated metabolite levels arise in large part due to a rewiring of the Krebs cycle upon immune cell activation ( Fig. 1) [10] . The Krebs cycle was first proposed by Hans Adolf Krebs in 1937 and is the primary oxidative pathway for acetyl coenzyme A (acetyl-CoA) derived from carbohydrates, fats and amino acids in aerobic organisms [11, 12] . The Krebs cycle is referred to as an amphibolic pathway, which is defined as a pathway that participates in both anabolic and catabolic processes. As such, it can be considered a nexus for integrating multiple anabolic and catabolic pathways, including glycolysis, gluconeogenesis, transamination, deamination, b-oxidation and lipogenesis [13] .
The Krebs cycle occurs in the mitochondrial matrix and is comprised of several enzymes, namely, citrate synthase (CS), aconitase (ACO), isocitrate dehydrogenase (IDH), a-ketoglutarate dehydrogenase (OGDH), succinyl-CoA synthase, succinate dehydrogenase (SDH), fumarase (FH) and malate dehydrogenase (MDH) [14] . As mentioned, acetyl-CoA can be derived from many sources, including glucose [13] . Glucose is catabolised to pyruvate, via glycolysis, prior to decarboxylation by the pyruvate dehydrogenase complex (PDH) to form the two-carbon compound acetyl-CoA and the cofactor NADH [13] . Three major products of the Krebs cycle are NADH, GTP and FADH 2 (generated by SDH) [15] . NADH and FADH 2 are extremely important as they are reducing equivalents that can transfer electrons to the electron transport chain (ETC.), a series of protein complexes found along the inner mitochondrial membrane (IMM) [15] . Transfer of electrons along the ETC. occurs via a series of redox reactions that leads to the pumping of protons (H + ) across the inner membrane to generate the mitochondrial membrane potential (MDw). Successful transfer of electrons is required to support formation of an electrochemical gradient that drives OXPHOS and highly efficient ATP production via ATP synthase [15] .
For a full turn of the cycle to be completed, a series of eight enzymatic reactions are required (Fig. 1) . The first step, catalysed by CS, is referred to as an aldol condensation reaction, whereby acetyl-CoA and oxaloacetate are converted to citrate [13] . Citrate is then converted to isocitrate by aconitase in a two-step reaction that first produces cis-aconitate via a dehydration reaction, which subsequently undergoes rehydration to form isocitrate [13] . The third reaction is catalysed by IDH, whereby isocitrate is decarboxylated to form a-ketoglutarate, CO 2 and NADH [13] . This step will be very important in future discussions of Krebs cycle rewiring. The next two reactions result in the conversion of a-ketoglutarate to succinate, via succinyl-CoA, which involves a second oxidative decarboxylation step followed by substrate-level phosphorylation (SLP), catalysed by a-ketoglutarate dehydrogenase and succinyl-CoA synthase respectively [13] . Like the third reaction, the flavin-dependent dehydrogenation of succinate to fumarate by SDH is also of the utmost importance when discussing metabolic reprogramming of the Krebs cycle in activated macrophages [13] . The final two steps of the cycle involve the hydration of the a,b-unsaturated C=C double bond of fumarate to form malate, catalysed by FH, and regeneration of oxaloacetate from malate by MDH [13] . The conversion of malate to oxaloacetate also produces NADH and the regeneration of oxaloacetate completes the cycle as it can then react with newly generated acetyl-CoA to form citrate, hitherto starting another round of reactions [13] .
As previously mentioned, the Krebs cycle is amphibolic and so diversion of nutrients towards the cycle (anaplerosis) or removal of intermediates to feed into biosynthetic pathways (cataplerosis) can be dictated by environmental cues, such as proinflammatory stimuli and nutrient availability, through modulation of the activity and expression of these TCA cycle enzymes. It is now appreciated that resting macrophages and DCs utilise OXPHOS and an intact TCA cycle to generate ATP and meet the bioenergetic demands of the cell [5, 10, 16] . However, in response to LPS (or LPS in combination with interferon-gamma (IFN-c)), we see a dramatic rewiring of the Krebs cycle in macrophages, as identified by the accumulation of the Krebs cycle intermediates citrate, succinate and fumarate [8, 10, 17] . The importance of these metabolites in immune cell function will now be discussed in turn.
Citrate metabolism and inflammation
Citrate as a signal for ROS and NO production It has been proposed that the accumulation of citrate in macrophages is in part caused by a break point in the TCA cycle at IDH (Table 1) [8, 10, 17] . Using an integrated high-throughput transcriptional metabolic profiling and analysis pipeline (CoMBI-T), Jha et al. [10, 17] observed significant downregulation of Idh mRNA and a decreased pool of a-ketoglutarate. This suggested a reduction in isocitrate to a-ketoglutarate conversion constituting the first breakpoint in the cycle. To further examine metabolic flow through IDH, stable isotopic labelling experiments with U- 13 Cglucose and U-13 C-glutamine was carried out [10, 17] . This further validated the CoMBI-T results as 20% of citrate labelled after 4 h of stimulation was synthesised from glucose, whereas no glucose-derived carbons were found in a-ketoglutarate [10, 17] . Reverse flow through IDH was also undetectably low based on the absence of glutamine-derived carbon labelling in citrate [10, 17] . This breakpoint has also been observed in LPSactivated DCs utilising 1,2 13 C-glucose tracing [5] . A key functional outcome of the switch to glycolysis and the repression of IDH is the channelling of pyruvate into the TCA cycle to form citrate [5, 8, 10, 21] . In macrophages, glucose-derived pyruvate undergoes oxidation via PDH to form citrate in mitochondria, despite HIF1a induction, which is known to induce pyruvate dehydrogenase kinase 1 (PDK1), an inhibitor of PDH activity [21] . Notably, treatment of macrophages with LPS increases the expression of the mitochondrial citrate carrier (CIC), also known as solute carrier family 25 member 1 (Slc25a1), via activation of two NF-jB binding sites in the CIC promoter [18] . CIC catalyses the efflux of mitochondrial citrate in exchange for cytosolic malate, thus leading to accumulation of citrate in the cytosol (Table 1 ; Fig. 2 ) [18] . Genetic silencing of CIC or inhibition with the specific inhibitor, 1,2,3-benzentricarboxylic acid (BTA), leads to a marked reduction in NO and ROS production [18] . Although the mechanism by which citrate regulates NO and ROS is unknown, the authors propose that the observed effects can be explained based on the role of citrate in intermediary metabolism. In the cytosol, glucose-derived citrate can be converted to oxaloacetate and acetyl-CoA via ATPcitrate lyase (ACLY) [19] . In a follow-up study, Infantino et al. [32] found that ACLY was also induced in response to LPS and that genetic silencing and inhibition of ACLY activity similarly led to decreases in both NO and ROS levels ( Table 1 ). The authors suggest that oxaloacetate itself may be converted to pyruvate in a two-step reaction involving cytosolic MDH and malic enzyme (ME), with NADPH being an important product [18] . However, evidence directly implicating citrate metabolism in regulating NO and ROS levels via NADPH has thus far been lacking. Another issue that must be noted is that no reverse or direct flow through ME has been detected in macrophages treated with LPS and IFN-c [10] .
Acetylation, de novo lipogenesis and prostaglandin synthesis
In addition to being an important signal for NO and ROS production, reprogramming of citrate metabolism is also essential to support acetyl-CoA production and de novo lipogenesis (lipid biosynthesis) in macrophages and DCs [5, 8, 10, 20] . Cytosolic acetyl-CoA derived from citrate ( Fig. 2) is an important cofactor for acetyltransferases, enzymes that catalyse the transfer of acetyl groups to lysine residues found on multiple proteins with distinct biological functions [19] .
Acetylation is an important post-translational modification known to be involved in sculpting the epigenome via modification of histones, a process regulated by ACLY [19] . Interestingly, genetic ablation of ACLY resulted in the suppression of genes involved in glycolysis and subsequently decreased glucose consumption [19] . These findings illustrate the crucial role of ACLY in linking cellular metabolism to the regulation of gene expression [19] . Citrate itself has also been shown to be an inhibitor HIF asparaginyl hydroxylase (FIH), an important regulator of HIF1a coactivator p300 acetyltransferase and HIF1a activity [33] . While no direct link between citrate/acetyl-CoA and glycolytic reprogramming has been shown in macrophages or DCs, work on other cell types suggest this may be an appealing avenue of investigation. However, acetylation has been shown to play an important role in the regulation of IL-6 and IL-10 in macrophages [34, 35] . In paraquat (PQ)-treated macrophages, induction of IL-6 was found to be dependent on histone acetylation, as histone deacetylase (HDAC) inhibition enhanced expression of Il6 mRNA, whereas histone acetyltransferase (HAT) inhibition blocked its induction [35] . Acetylation of a-tubulin in LPS-activated macrophages was also shown to regulate IL-10 induction [34] . Inactivation of the tubulin acetyltransferase MEC17 was found to inhibit IL-10, while inhibition of HDAC6 or stimulation of HDAC6-deficient macrophages with LPS led to IL-10 hyperinduction via p38 MAPK and Sp1-dependent Il10 transcription [34] .
Acetyl-CoA can also be funnelled into lipid biosynthesis via acetyl-CoA carboxylase (ACC), an enzyme that catalyses the conversion of acetyl-CoA to malonyl-CoA (Table 1 ; Fig. 2 ) [19, 32] . Malonyl-CoA is then used as a substrate for fatty acid biosynthesis by fatty acid synthase (FASN), the rate-limiting enzyme responsible for synthesis of palmitate, the precursor to 
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Histone demethylases b-glucan-induced fumarate accumulation inhibits enzymatic activity Enhanced cytokine production [31] all lipids [12, 36] . In DCs, citrate is funnelled from the Krebs cycle into de novo lipid biosynthesis that is subsequently required for membrane expansion of the endoplasmic reticulum (ER) and Golgi [5] . Inhibition of ACC with TOFA, or FASN with the inhibitor C75, blocked this process, which is essential for the synthesis, transport and secretion of TLR-induced cytokine production, e.g. IL-6, TNF-a and IL-12p40, and for LPS-induced surface expression of CD40, CD86 and MHC class I and class II proteins [5] . Inhibition of fatty acid synthesis in DCs also inhibited secretion of the inflammatory lipid-mediator prostaglandin E 2 (PGE 2 ), which is derived from arachidonic acid synthesis and induction of cyclooxygenase 2 (COX2) [5, 18, 32] . Similarly, genetic ablation or inhibition of CIC or ACLY also led to an inhibition of endogenous PGE 2 synthesis in LPS-activated macrophages, which has recently been shown to be essential for LPS induction of pro-IL-1b [18, 32, 37] . The requirement of citrate, FASN and fatty acid synthesis in macrophage activation has been further compounded by the discovery of C13orf31 (FAMIN), a protein that forms a complex with FASN on peroxisomes and promotes flux through de novo lipogenesis, although the precise mechanism by which it achieves this is still unknown (Table 1 ) [20] . Cader et al. [20] demonstrated that FAMIN association with FASN was an important regulator of macrophage ROS production, bactericidal activity and cytokine production in LPS-treated macrophages and in a murine in vivo endotoxin shock model. Intriguingly, FAMIN was identified through the study of consanguineous families that carried single nucleotide polymorphisms (SNPs) in the gene and is associated with an increased risk for the inflammatory diseases, systemic juvenile idiopathic arthritis, leprosy and Crohn's disease [20] . Malonyl-CoA like acetyl-CoA can also modify lysine residues, in a process termed malonylation (Fig. 2) [38, 39] . Protein lysine malonylation is a highly conserved protein modification; however, it remains largely understudied [39] . In two models of type 2 diabetes, proteomic analysis of liver tissue was used to identify 573 malonylated lysine sites from 268 proteins, many of which were metabolic enzymes involved glycolysis, e.g. glyceraldehyde 6-phosphate dehydrogenase (GAPDH) and lipid metabolism, e.g. ACLY [39] . However, it remains to be seen if there is a role for malonylation in metabolic remodelling during inflammation.
Citrate-derived itaconate as an immunomodulator and antibacterial agent
One of the most thought-provoking examples of an immunomodulatory metabolite that results from Krebs cycle rewiring is citrate-derived itaconate [10, [21] [22] [23] [24] . While it has long been used in the industrial polymer Citrate metabolism and inflammation. In macrophages and DCs, citrate that accumulates due to Krebs cycle rewiring can be exported from mitochondria via CIC. In the cytosol, citrate can be converted to acetyl-CoA and oxaloacetate by ACLY leading to NO and ROS production by some unknown mechanism. Furthermore, acetyl-CoA can be used for acetylation by acetyltransferases or converted to malonyl-CoA via ACC. Similar to acetylation, malonly-CoA can be used to malonylate lysine residues or it can feed into fatty acid synthesis through FASN. Lipogenesis is essential for the production/secretion of cytokines and PGE 2 . In the mitochondrial matrix, citrate can be converted to itaconate, via cis-aconitate, by IRG1. Itaconate may then act to inhibit SDH and cytokine production or be exported from mitochondria to inhibit microbial IDH and the glyoxylate shunt.
arena [40] , the first relevant discovery regarding itaconate's role in cellular immunity came when Lee et al. [41] cloned IRG1, which was found to be significantly upregulated upon treatment of peritoneal macrophages with LPS. It was not until 2011 that the production of itaconate was described in two separate immune contexts, which included in the lungs of mice that had been infected with Mycobacterium tuberculosis [42] and its secretion into the supernatant of the macrophage-like cell line, RAW264.7, that had been stimulated with LPS [43] . Michelucci et al. [25] went on to demonstrate that IRG1 was the enzyme responsible for itaconate production in a gain-and-loss of function approach in both human and mouse macrophages. As IRG1 catalyses the decarboxylation of cis-aconitate to form itaconate (Table 1 ; Fig. 2 ), IRG1 was officially renamed cis-aconitate decarboxylase (CAD) [10, 25] . Interestingly, Michelucci et al. [25] showed that genetic silencing of Irg1/Acod1 in macrophages infected with Salmonella enterica decreased intracellular itaconate levels and reduced antibactericidal activity. The antibacterial function of itaconate had been first demonstrated in the 1970s, as it effectively inhibited isocitrate lyase (ICL) from Pseudomonas indigofera under low glucose conditions; however, this property of itaconate did not garner interest until its discovery as a naturally occurring immunometabolite [25, 44, 45] . In addition to P. indigofera, exogenous itaconate has since been shown to inhibit in vitro growth of numerous pathogenic bacteria including M. tuberculosis, Staphylococcus aureus, S. enterica, Legionella pneumophillia and Acinetobacter baumannii [25, 42, 46] . In another example in Yersinia pestis and Pseudomonas aeruginosa, itaconate degradation (mediated by three enzymes -itaconyl-CoA transferase, itaconyl-CoA hydratase and (S)-citramalyl-CoA lyase) is critical for bacterial survival and pathogenicity [47] .
Isocitrate lyase itself is a key enzyme of the glyoxylate shunt, an anabolic variation of the Krebs cycle that circumvents the two decarboxylation reactions and is used as a mechanism for survival in glucosepoor conditions in some plants and microorganisms [48, 49] . The importance of ICL as a virulence factor in microorganisms has been clearly demonstrated with the pathogenic fungus, Candida albicans [49] . Upon infection, C. albicans undergoes phagocytosis by macrophages resulting in the upregulation of ICL1; however, C. albicans strains with a mutant ICL1 are significantly less virulent than wild-type strains [49] . Similarly, deletion of both isoforms of ICL, ICL1 and ICL2, in M. tuberculosis resulted in complete impairment of intracellular replication in macrophages and its rapid elimination from the lungs of mice, while inhibition of ICL also inhibited growth in macrophages [50] . Despite the importance of ICL in infection and the evidence implicating itaconate as an antimicrobial agent, there has been some debate around the physiological relevance of studies using itaconate to inhibit bacterial cell growth [51] . This has arisen from inconsistencies between the concentrations of itaconate used in vitro, ranging from 5 mM to 100 mM, and the intracellular concentrations identified in macrophages, ranging from 40 lM to 80 mM [51] . However, many studies have used itaconate in the 10 mM range, a concentration close to some previous reports [43] , while induction of IRG1 by both type I and type II interferons in L. pneumophillia-infected macrophages mediates itaconate production and restricts intravacuolar growth of the bacteria [46] . As such, the role of itaconate as a physiologically relevant antibacterial metabolite remains an open question to be explored.
Despite the known bactericidal activity of itaconate, its role in regulating macrophage function remained unknown. Recent studies have brought to light the possibility that itaconate is an important immunomodulator [21, 24, 52, 53] . Importantly, LPS-stimulated BMDMs treated with methyl ester derivative of itaconate, dimethyl itaconate (DMI), exhibited potent inhibition of proinflammatory mediators including NO, ROS and the cytokines IL-1b, IL-12p70, and IL-6; however, no effect on TNF-a levels was observed [24] .
Furthermore, LPS-activated Irg1-deficient BMDMs exhibited a boost in the production of IL-12, IL-6, NO and under conditions that stimulate the NLRP3 inflammasome, increased IL-1b and IL-18 [24] . An increase in Hif1a mRNA and HIF1a protein levels was also observed in Irg1-deficient BMDMs, a critical regulator of aerobic glycolysis and IL-1b production [8, 24] . The role of IRG1 and itaconate as negative regulators of inflammation is further supported by the findings that IRG1 suppresses the production of ROS, TNF-a, IL-6 and IFN-b in LPS-tolerised macrophages [52] . Li et al. (2013) found that the effect of IRG1 on cytokine and interferon production was through ROS-mediated induction of A20, as supplementation of ROS levels in Irg1-knockdown macrophages boosted A20 levels and abrogated the breaking of endotoxin tolerance [52] . Additionally, IRG1 has also been found to mediate the immunosuppressive effects of CO-releasing molecule 2 (CORM2)-induced haem oxygenase 1 (HO-1) on LPS-induced TNF-a production in macrophages and in a murine LPS sepsis model [53] . Interestingly, IRG1 also appears to play a major role in embryo implantation in the womb, a process thought to require suppression of the host immune system [51, 54, 55] . These findings suggest that the production of itaconate by IRG1 in macrophages acts as a negative regulator of inflammation and crucially provides the first link between itaconate signalling and the modulation of proinflammatory cytokine production. While the impact of itaconate on DCs has yet to be explored, it has been observed to accumulate in response to LPS [5] , and future studies on how this regulates DC effector function and their interaction with adaptive immune cells could yield some fascinating discoveries.
In addition to the breakpoint at IDH, Jha et al. [10, 17] described a second breakpoint in the TCA cycle using U- 13 C-glutamine, as approximately 35% of the pool of succinate but only 22% of malate could be attributed to glutamine in LPS-activated macrophages, suggesting inefficient succinate-to-fumarate transition at SDH. Lampropoulou and coworkers argued that itaconate accumulation prevents succinate oxidation via SDH (Fig. 2) , thus limiting inflammation by blocking the generation of ROS derived from reverse electron transport (RET) and complex 1, a process that will be discussed in detail later in the review [24] . Itaconate was first demonstrated to competitively inhibit SDH over 60 years ago [36] and this prompted speculation regarding its role in regulating cellular metabolism and decreased flux through SDH [24, 56] . Exogenous addition of DMI, to both resting and activated macrophages and the lung adenocarcinoma cell line A549, was found to be sufficient to induce succinate accumulation [23, 24] . Furthermore, itaconate was found to competitively inhibit purified SDH, while Irg1 knockout BMDMs, which can no longer generate endogenous itaconate, had significantly decreased succinate levels and increased oxygen consumption rates (OCR) in response to LPS [24] . Together these papers offer a molecular explanation for the second breakpoint in the Krebs cycle and succinate accumulation.
However, it must also be noted that itaconate is only regarded as a weak competitive inhibitor of SDH [22] raising the question as to how physiologically relevant the findings are. Even more concerning is the recent discovery that DMI, the tool compound used in these studies, is not metabolised to itaconate intracellularly [57] . It was also found that [ 13 C] itaconate in cell culture media was sufficient to increase intracellular levels of unlabelled succinate, with no evidence of cellular uptake [57] . The authors posited that this could be due to a receptor-mediated effect especially given the discovery of metabolites signalling via Gprotein-coupled receptors (GPCRs), for example the succinate receptor SUCNR1 (previously GPR91) [58] .
If an itaconate receptor did exist, the results of this study could indicate the Irg1 knockout phenotype is in part due to a loss of autocrine or paracrine signalling by secreted itaconate. Importantly, methyl esterification is also predicted to increase the electrophilicity of itaconate and thus it may behave as a cysteine alkylating agent [57] . This suggests the metabolic effects of DMI observed in macrophages do not appear to be due to intracellular itaconate accumulation, but may instead be due to electrophilic inactivation of metabolic enzymes. This idea is partially supported as Lampropoulou et al. [24] reported an upregulation of genes involved in Phase II conjugation, glutathione conjugation and biological oxidations upon treatment with DMI. As such, improved methods of delivering itaconate to macrophages and other immune cells will be important to understand the metabomodulatory properties of this metabolite.
Succinate as an inflammatory signal during inflammation
Succinate, HIF1a stabilisation and IL-1b production An important advancement in the field of immunometabolism was the discovery of succinate accumulation in activated macrophages and its signalling through HIF1a (Table 1 ; Fig. 3 ) [8] . Tannahill et al. [8] showed that the principal source of succinate in LPS-activated macrophages was derived from glutamine-dependent anaplerosis, while a role for the caminobutyric acid shunt was also identified. HIF itself is a highly conserved member of the basic helix-loophelix (bHLH) family of transcription factors and considered the master transcriptional regulator of the cellular response to hypoxia [59] [60] [61] . Under hypoxic conditions, HIF forms a heterodimeric complex consisting of an a and b subunit [59] [60] [61] . When O 2 levels are high (normoxic), HIF is tightly regulated through hydroxylation of conserved proline residues in the HIF a subunit by prolyl hydroxylases (PHDs) [59] [60] [61] . Importantly, PHD enzymatic activity is highly dependent on the Krebs cycle intermediate a-ketoglutarate and O 2 [59, 60] . Hydroxylation of HIF facilitates its ubiquitination, and subsequent degradation via the 26S proteasome, by the von Hippel-Lindau (VHL) E3 ubiquitin ligase [59] [60] [61] . In 2005, a breakthrough study on SDH-deficient tumours demonstrated that succinate acted as an oncometabolite to drive the Warburg effect and tumour formation [60] . This effect was credited to succinate's ability to stabilise HIF1a through product inhibition of PHDs, even in the absence VHL mutations [60] . Analogous to SDH-deficient tumours, Tannahill et al. [8] showed that the accumulation of succinate in macrophages acts to stabilise HIF1a by direct inhibition of cytosolic PHD activity, even under normoxic conditions. It was demonstrated that the proinflammatory cytokine IL-1b contained HRE elements in its promoter and that succinate acted as a danger signal or alarmin to sustain production of IL1b through induction of HIF1a [8] . Interestingly, a boost in protein succinylation, a modification akin to acetylation and malonylation, was also reported [8] . However, the functional importance of this modification and the role it may play in metabolic reprogramming has yet to be established. The findings by Tannahill et al. emphasised the importance of Krebs cycle rewiring in supporting glycolytic reprogramming, via HIF1a, and the crucial role of Krebs cycle intermediates as inflammatory signalling moieties.
Succinate dehydrogenase, ROS and IL-1b production
More recently, it has been suggested that succinate oxidation by SDH also plays an integral role in HIF1a stabilisation and IL-1b production, via ROS production (Table 1) [26] . Previously, it has been demonstrated that inhibition of the SDHB subunit of SDH, either by pharmacological inhibition or RNA interference, increases HIF1a in a ROS-dependent manner by inhibiting PHDs [62] . In addition to a-ketoglutarate and O 2 , PHD activity is dependent on Fe 2+ as a cofactor, as a result, ROS-mediated oxidation of Fe 2+ to Fe 3+ inhibits PHDs leading to HIF1a stabilisation [63] . Interestingly, Mills et al. [26] found that inhibition of SDH with the competitive inhibitor dimethyl malonate (DMM) potently blocked mitochondrial ROS (mtROS) production from complex I, HIF1a stabilisation and induction of IL1-b, while boosting the anti-inflammatory cytokine IL-10. Indeed, complex I had previously been shown to be a site of ROS production in LPS-treated macrophages, a process inhibited by the antidiabetic drug metformin [64] . DMM also exerted its anti-inflammatory effects in an LPS sepsis model by blocking IL-1b and boosting IL-10, indicating SDH activity plays an important role in the inflammatory response in vivo [26] . Furthermore, it was found that mtROS production was dependent on hyperpolarisation of the IMM, driven by increased glycolytic ATP, and treatment of LPS-stimulated macrophages with the proton ionophoric uncoupling agent, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP), was sufficient to block ROS, HIF1a and IL-1b [26] .
Mills et al. [26, 65] argued that inhibition of SDH by DMM blocks ROS generated by RET (Fig. 3) , a process first observed in a model of ischaemia-reperfusion (IR) injury. During ischaemia, succinate accumulates due to reversal of SDH directionality, but upon Fig. 3 . Succinate as an inflammatory signal during inflammation. Succinate accumulation in response to LPS acts via three primary mechanisms to regulate IL-1b production. Firstly, succinate derived from glutamine anaplerosis and the c-aminobutyric acid shunt can be oxidised by SDH to drive RET and ROS production from complex I, an effect aided by glycolytic ATP, ATP synthase and membrane hyperpolarisation. Succinate can also be exported from mitochondria into the cytosol, whereby it can synergise with ROS to directly inhibit PHD activity and stabilise HIF1-a. Succinate can also be secreted from the cell where it can bind SUCNR1, which acts as an autocrine and paracrine sensor for succinate, as part of a positive feed forward loop to sustain IL-1b, a process thought to be dependent on elevated Ca 2+ and ERK1/2 activation.
reperfusion, SDH rapidly oxidises accumulated succinate resulting in the overreduction of the coenzyme Q (CoQ) pool [65] . Excessive reduction of CoQ forces electrons to flow backwards through complex I to generate O 2 -, a process inhibited by DMM [65] . RET has also been implicated as a signalling mechanism in a variety of settings since it was first described in IR, such as in the ageing process in Drosophila [66] and oxygen sensing in the carotid body [67] . To support this model of ROS induction, Mills et al. [26] utilised BMDMs from mice expressing the enzyme alternative oxidase (AOX), which enables electrons to bypass the block at CoQ, thus limiting RET. Intriguingly, LPStreated AOX-expressing macrophages limited IL-1b and HIF1a induction, an effect attributed to decreased RET-driven ROS production [26] . The role of SDH and the ETC. in regulating immune signalling and ROS production was further supported by the observation that macrophages infected with Escherichia coli and S. enterica remodelled complex I-containing supercomplexes [27] . Garaude et al. [27] reported that inhibition of SDH with DMM impaired the antibactericidal activity of macrophages infected with E. coli. While no direct evidence was provided, both Lampropoulou et al. and Garaude et al. [24, 27] also suggested inhibition of RET, by DMM and itaconate respectively, as the molecular mechanism governing their observed phenotypes. Together these observations provide a striking role for SDH and succinate oxidation in regulating the inflammatory response and macrophage effector functions.
The succinate receptor (SUCNR1) and inflammation
It has also become apparent that another role for succinate accumulation during inflammation is as the cognate ligand for the G-protein-coupled receptor, GPR91, which has since been classified the succinate receptor SUCNR1 (Table 1) [28] . In 2004, He et al. [28] made the striking discovery that the Krebs cycle intermediates succinate and a-ketoglutarate, present extracellularly, acted as ligands for the previously orphan receptors, GPR91 and GPR99, respectively. GPR91 expression was found to be distributed in a plethora of mouse tissues including the kidney, the spleen, the liver and the small intestine [28] . The authors showed that succinate exhibited signalling functions beyond its conventional role in bioenergetics, acting as a hypertensive agent through GPR91 and modulation of the renin-angiotensin system [28] . Subsequent studies have also found SUCNR1 to be expressed on the plasma membrane (PM) in macrophages and DCs [29, 30] .
Since the discovery of SUCNR1, the elucidation of the signalling cascades elicited by binding of succinate has begun to emerge [58, 68, 69] . Robben et al. [70] showed GPR91 to be a Gi-and Gq-coupled receptor using the inhibitors pertussis toxin (PTX) and YM254890 in kidney-derived MDCK cells [71] . Sundstr€ om et al. confirmed that GPR91 was an Ga(i)-and Ga(q)-coupled receptor resulting in the inhibition of 3 0 -5 0 -cyclic adenosine monophosphate (cAMP) and inositol triphosphate (IP3) formation [58, 68, 69] . The agonist-mediated effects of SUCNR1 stably expressed in the human embryonic kidney (HEK) 293 cell line were detected using dynamic mass redistribution (DMR) and found to be sensitive to PTX [58, 68, 69] . Inhibition of SUCNR91 signalling with PTX, edelfosine and U73122 also demonstrated the importance of SUCNR1 to elevate intracellular calcium (Ca 2+ ) via IP3 generated by phospholipase C b (PLCb) [58, 68, 69] . Similar signalling pathways have also been uncovered in other SUCNR1-positive cell types including adipocytes treated with lipolytic hormones [72] and hematopoietic progenitors [71] , which drove proliferation via activation of ERK1/2. Interestingly, succinateinduced responses in cardiac myocytes and platelets involved the induction of protein kinase A (PKA) through the Gs/cAMP pathway, suggesting cell typespecific coupling of G proteins to SUCNR1 [73, 74] . Even more importantly, SUCNR1 stimulated with succinate was found to induce intracellular Ca 2+ mobilisation and phosphorylation of ERK1/2 in DCs, highlighting its functionality in immune effector cells and inflammation [30] .
In 2008, the first line of evidence that succinate signalling through SUCNR1 was an important inflammatory mechanism (Fig. 3) was proposed [30] . Rubic et al. [30] demonstrated that succinate acted in synergy with TLR agonists to boost inflammatory cytokine expression in DCs [30] . Specifically, succinate boosted TNF-a levels, in synergy with TLR3 agonist poly(I:C) and TLR7 agonist imiquimod, while it also potentiated IL-1b levels in conjunction with LPS [30] . In addition, SUCNR1 was also found to be involved in DC chemotaxis, as monocyte-derived DCs (moDCs) exhibited enhanced migration to draining lymph nodes when treated with succinate [30] . Furthermore, succinate was also found to enhance antigen presentation by DCs and antigen-specific activation of helper T cells, an effect abolished in SUCNR1 KO DCs [30] . More recently, SUCNR1 has been shown to be an important regulator of macrophage activation [29] . In response to inflammatory insults, macrophages were shown to export succinate out of the cell into the extracellular milieu [29] . Importantly, LPS stimulation upregulated expression of SUCNR1, which acted as an autocrine and paracrine sensor for succinate, and was required for the release of IL-1b, a process inhibited in SUCNR1-deficient macrophages [29] . Importantly, this positive feed forward loop was shown to be a driver of inflammation in an antigen-induced model of rheumatoid arthritis (RA), as succinate in the synovial fluid of RA joints acted through SUCNR1 to promote IL-1b production [29] . SUCNR1-deficient mice have also been shown to exhibit reduced arthritic disease in an ovalbumin-induced arthritis model [75] . Interestingly, these mice are also more susceptible to allergic contact dermatitis (ACD) attributed to increased mast cell activation [75] . These results among others have prompted the suggestion that GPR91 antagonism may constitute a promising therapeutic approach in RA patients and other inflammatory disorders; however, the observation of elevated ACD suggests a possible anti-inflammatory role for succinate and SUCNR1 in some allergic disorders, something that must be considered when moving forward to the clinic [29, 75] .
With these findings, the role of succinate and SUCNR1/GPR91 signalling in inflammation, under both physiological and pathophysiological settings, is slowly being unravelled. Coupled to its intracellular signalling capacity, succinate has placed itself as one of the most crucial mediators of inflammation in innate immunity and provides a startling example of how Krebs cycle rewiring and Krebs cycle intermediates dictate the effector functions of macrophages and DCs. This field is currently in its infancy and so these discoveries open up the possibility that other TCA cycle metabolites, and their derivatives, may act as receptor ligands to modulate important physiological processes, such as the inflammatory response.
Fumarate, the epigenome and trained immunity
Glutaminolysis, fumarate and cytokine production Somewhat like LPS, another microbial product b-glucan, which occurs in the cell wall of fungi, will induce glycolytic reprogramming and rewiring of the Krebs cycle [31, 76, 77] . Similarly, b-glucan will cause the accumulation of the Krebs cycle intermediates succinate and fumarate (Fig. 4) [31] . Interestingly, a-ketoglutarate is an important cofactor for a-ketoglutarate-dependent dioxygenases, a family of enzymes involved in the regulation of DNA and histone demethylation [31, [78] [79] [80] [81] . Members of this family include the Jumonji C-domain-containing histone demethylases (JMJDs), involved in histone demethylation, and the ten-eleven translocation (TET) family of 5mC hydroxylases, which are involved in DNA demethylation [31, [78] [79] [80] [81] . These dioxygenases generate succinate from a-ketoglutarate as a product and so their activity is subject to feedback inhibition and dependent on the ratio of a-ketoglutarate to succinate in the cell [78] [79] [80] . Additionally, JMJD and TET enzymatic activity can also be competitively inhibited by fumarate [78, 81] . As such, alterations in the levels of these Krebs cycle intermediates can alter the epigenetic landscape of a cell [78] [79] [80] . Arts et al. [31] showed that accumulation of fumarate in response to b-glucan was essential for trained immunity in macrophages. Mechanistically, it was proposed that glutamine anaplerosis was the source of elevated fumarate in these cells based on biochemical methods and the inhibition of glutaminolysis by the glutaminase inhibitor BPTES [31] . Treatment of cells with the cell permeable fumaric acid ester monomethyl fumarate (MMF) was shown to induce an epigenetic programme with similarities to b-glucan-induced training [31] . Monomethyl fumarate was also shown to boost TNF and IL-6 production upon LPS restimulation of b-glucan-trained macrophages [31] . The authors proposed that fumarate accumulation acted to inhibit KDM5 histone demethylases (Table 1) , thus increasing the levels of H3K4 me3 at the promoters of Tnf and Il6 [31] . As such, this study presented the first link between Krebs cycle rewiring and epigenetic reprogramming in trained immunity and inflammation. As previously mentioned, fumarate has also been reported to accumulate in LPS-activated macrophages and DCs; however, the consequences of this on inflammatory signalling and effector function have yet to be determined. One possibility is as an endogenous activator of Nrf2, a known negative regulator of inflammation and cytokine production in macrophages [82] . Ashrafian et al. [83] have previously shown fumarate to be cardioprotective in a model of heart ischaemia/reperfusion, acting to increase the antioxidant response via Nrf2. Whether fumarate has a similar effect in macrophages or DCs has yet to be determined.
Conclusions and perspectives
Recent findings on the role of Krebs cycle intermediates during inflammation have advanced our understanding of the complexity of immunometabolism. A precedent has now been set for metabolites generated by innate immune cells to have distinct functions as signalling entities and antibactericidal agents, beyond their role in bioenergetics. Our recent understanding of the integration of the immune system with cellular metabolism has in large part been owed to great technological advancements and improvements in instrumentation, such as those that have enabled systems level approaches to determine global gene and protein expression in response to inflammatory stimuli. Moreover, advancements in mass spectrometry and computational analysis now allows for detailed molecular modelling and determination of the metabolome in complex biological samples [8, 10] . On a translational level, insight into the interface of metabolism and immunity could uncover new targets with promising therapeutic potential in transplantation, infection and inflammatory and autoimmune disorders. For example, succinate signalling through SUCNR1 has been implicated in the autoimmune disorder RA [29] with this discovery opening a new window of opportunity for the development of SUCNR1 antagonists in the treatment of this debilitating disease [29] . Furthermore, the use of metabolites as biomarkers for immunerelated diseases may become integral in clinical settings due to the uncovering of abnormal metabolite levels in diseased tissues, such as the rheumatoid joint [29] and in the colon of ulcerative colitis patients [84] .
On a basic level, a key discovery regarding Krebs cycle rewiring is the assumption of two breakpoints at IDH and SDH, as previously delineated. However, it is important to note that this view may be overly simplistic as itaconate has also been shown to abolish mitochondrial substrate-level phosphorylation (SLP) [22] . Nemeth et al. [22] postulated that the formation of itaconyl-CoA from itaconate creates a 'CoA trap' that negatively regulates the supply of succinyl-CoA, shifts equilibrium towards utilisation of ATP (or GTP) by succinyl-CoA synthase and depletes ATP (or GTP) levels, thus decreasing important cofactors for thioesterification. This suggests an additional impairment of the TCA cycle may also exist at succinyl-CoA synthase. Interestingly, Liu et al. [85] also demonstrated that LPS and IFN-c stimulation of macrophages results in the downregulation of multiple TCA cycle genes in addition to Idh, including SdhA, SdhaB and SdhC, which suggests greater transcriptional regulation of the Krebs cycle is occurring. It is also important to note that while SDH activity appears to be reduced, it is still functionally active, unlike IDH, and so it could be argued that only one true breakpoint has thus far been identified. Furthermore, SDH activity has been shown to be essential for mediating the immune response in macrophages, as previously discussed [26, 27] . Evidently, the molecular mechanisms governing Krebs cycle remodelling are just beginning to be unearthed and warrant further investigation.
Despite technological advancements, there are still limits to our capabilities based on techniques currently applied in laboratories across the world. For example, one big advancement required to propel our understanding of immunometabolism to the next phase is moving away from whole-cell analysis of the metabolome towards looking at the dynamics of organellespecific metabolites. Recently, steps have been made in this direction. In a remarkable study, Chen et al. [86] described a workflow that included a specific method for the rapid isolation of mitochondria and the absolute quantification of matrix metabolites. This technique enabled the authors to compare the dynamics of the whole-cell metabolome with the mitochondrial matrix metabolome (MITObolome) across various states of ETC. disruption [86] . Furthermore, adaptation of this technique may be applicable to other cellular organelles and cell types in the future. Employment of techniques such as this to study immunometabolism could lead to great discoveries in how the metabolite composition of organelles changes during inflammation. Such information could lead to new understandings of how metabolites are trafficked and secreted, unearth new cellular metabolic networks and discover novel targets and interactors in cell signalling pathways. The future is bright for the field of immunometabolism and we can be certain that hugely important discoveries shall be made in both basic and translational immunological research.
